FPI-1523 is a novel β-lactamase inhibitor that has potent cross-class inhibition and clinical studies targeting MDR infections are warranted. It inhibited class A, C, and D β-lactamases with unprecedented k2/K values against OXA carbapenemases.
河北唯特医药科技有限公司
联系商家时请提及chemicalbook,有助于交易顺利完成!
河北唯特医药